DCTD Programs
FOLLOW DCTDLast Updated: 06/01/2016
2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Schedule of DCTD Presentations
Several DCTD staff members will present information at the ASCO Annual Meeting 
in Chicago, IL from June 3-7, 2016 via the following three presentation categories:
Oral Presentations
| Time | Title | Presenter | Location |
|---|---|---|---|
| Friday, June 3, 2016 | |||
| 4:25 PM - 4:45 PM | Extended Education Sessions: Practical Tips for Academic, Private, and Industry Career Tracks: Negotiating Contracts and Education Debt Management Government Perspective |
Percy Ivy, MD, Cancer Therapy Evaluation Program |
S404 |
| 5:05 PM - 5:25 PM | Extended Education Sessions: Practical Tips for Academic, Private, and Industry Career Tracks: Negotiating Contracts and Education Debt Management Education Debt: National Institutes of Health Loan Repayment Program |
Shakun Malik, MD, Cancer Therapy Evaluation Program |
S404 |
| Saturday, June 4, 2016 | |||
| 8:20 AM - 8:40 AM | Education Session: Divide and Conquer: Epithelial Gynecologic Cancers Beyond BRCA Emerging Data: Pulling It All Together for the Patient |
Elise Kohn, MD, Cancer Therapy Evaluation Program |
E450ab |
Poster Presentations
| Time | Title | Presenter | Location |
|---|---|---|---|
| Saturday, June 4, 2016 | |||
| 1:00 PM - 4:30 PM | Will a national communication campaign to increase awareness of clinical trials work?
|
Holly Massett, PhD, Cancer Therapy Evaluation Program |
Hall A; Abstract 6537; Poster Board 24 |
| Sunday, June 5, 2016 | |||
| 8:00 AM - 11:30 AM | Feasibility of molecular profiling based assignment of cancer treatment (MPACT): A randomized NCI precision medicine study.
|
Alice P. Chen, MD, Early Clinical Trials Development Program |
Hall A; Abstract 2539; Poster Board 239 |
| 8:00 AM - 11:30 AM | NCI-MATCH (Molecular Analysis for Therapy Choice) - a national signal finding trial.
|
Barbara A. Conley, MD, Cancer Diagnosis Program |
Hall A; Abstract TPS2606; Poster Board 298b |
| 8:00 AM - 11:30 AM | Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors.
|
Apurva Srivastava, PhD, Office of the Director/Frederick National Laboratory for Cancer Research |
Abstract 2553; Poster Board 253 |
| 1:00 PM - 5:00 PM | A phase 1 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.
|
Robert Meehan, MD, Early Clinical Trials Development Program |
Hall A; Abstract 2556; Poster Board 256 |
| Monday, June 6, 2016 | |||
| 8:00 AM - 11:30 AM | Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.
|
Geraldine O'Sullivan Coyne, MD, PhD, Early Clinical Trials Development Program |
Hall A; Abstract 11028; Poster Board 154 |
Meet-the-Expert Presentations
NCI Exhibit Booth # 5053
| Time | Topic | Presenter |
|---|---|---|
| Saturday, June 4, 2016 | ||
| 11:45 AM - 12:15 PM | Common Terminology Criteria for Adverse Events | Alice Chen, MD Early Clinical Trials Development Program |
| 10:15 AM - 10:45 AM | Effective Integration of Biomarker Studies in Early Phase Clinical Trials | Tracy Lively, PhD Cancer Diagnosis Program |
| Sunday, June 5, 2016 | ||
| 12:30 PM - 1:00 PM | Pediatric MATCH Q/A | Nita Seibel, MD Cancer Therapy Evaluation Program |
| Monday, June 6, 2016 | ||
| 10:15 AM - 10:45 AM | NCI's Exceptional Responders Initiative | Lyndsay Harris, MD Cancer Diagnosis Program |
| 11:00 AM - 11:30 AM | Reopening of NCI-MATCH | Alice Chen, MD |